Literature DB >> 1357809

Epidermal growth factor receptor and bladder cancer: a review.

D E Neal1, K Mellon.   

Abstract

Recently, expectations have been raised that molecular biological studies of human tumours may be of value in helping to predict future clinical behaviour, in terms of therapeutic response and long-term survival. The epidermal growth factor receptor (EGFr) is a cell surface receptor for EGF and transforming growth factor-alpha which is overexpressed by a number of human tumours. This article principally reviews previous investigations of the role of the epidermal growth factor receptor in bladder cancer and examines methods of detection, the correlation between EGFr status and known prognostic indicators and the value of assessing EGFr status in predicting clinical outcome in patients with bladder cancer. Recent studies of the c-erbB-2 proto-oncogene in bladder cancer and of cell cycling using Ki-67 are included.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357809     DOI: 10.1159/000282357

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  19 in total

Review 1.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 2.  Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance.

Authors:  B J Schmitz-Dräger; F Jankevicius; R Ackermann
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 3.  Growth factors in bladder cancer.

Authors:  M Liebert
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 4.  Sleeping beauty: awakening urothelium from its slumber.

Authors:  Zarine R Balsara; Xue Li
Journal:  Am J Physiol Renal Physiol       Date:  2017-01-25

5.  Contractile and cytoskeletal proteins in urinary bladder smooth muscle from rats treated with epidermal growth factor.

Authors:  L Vinte-Jensen; B Uvelius; E Nexø; A Arner
Journal:  Urol Res       Date:  1996

6.  Enhanced gene expression of transforming growth factor-alpha and c-met in rat urinary bladder cancer.

Authors:  M Inui; N Nishi; A Yasumoto; I Takenaka; H Miyanaka; K Matsumoto; T Nakamura; F Wada
Journal:  Urol Res       Date:  1996

7.  Chronic treatment with epidermal growth factor stimulates growth of the urinary tract in the rat.

Authors:  L Vinter-Jensen; M Smerup; P E Jørgensen; C O Juhl; T Orntoft; S S Poulsen; E Nexø
Journal:  Urol Res       Date:  1996

8.  Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response.

Authors:  Ramaswamy Bhuvaneswari; Yik Yuen Gan; Khee Chee Soo; Malini Olivo
Journal:  Mol Cancer       Date:  2009-11-02       Impact factor: 27.401

9.  FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Authors:  Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo H van der Kwast; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.